NASDAQ
3.63USD
+0.03 (+0.83%)
We have scored 5 news catalysts on Prelude Therapeutics Incorporated (PRLD) over the past 12 months. The biggest single-day move next to one of them came Nov 3, 2025, when PRLD closed +150.3%: “Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting”. Coverage across the window leans negative (average ticker sentiment −0.10). Most of the impact sits in institutional appeal and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
210.1M
P/E
—
EPS
—
Beta
0.96
52W range
1.17-6.83
Day range
3.41–3.69
Open
3.57
Prev close
3.60
Volume
288.6K
Avg volume
515.6K
Dividend
0.00
IPO
2020-09-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Prelude Therapeutics Incorporated — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PRLD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
